Glioblastoma (GBM) is a highly aggressive and lethal brain cancer, notorious for its rapid growth, high recurrence, and significant resistance to conventional therapies. Approximately 80,000 new primary brain tumor cases are diagnosed annually in the U.S., with GBM accounting for about 15% and carrying a morbidity rate exceeding 70%.
“SiNON’s Carbon Nanoparticle technology is designed to overcome critical barriers in glioblastoma treatment, delivering highly targeted and effective therapies.”
SiNON Nano Sciences began with a focus on Glioblastoma Multiforme (GBM), an aggressive brain cancer. As our research progressed, we identified a critical need to address brain metastases from high-risk cancers like lung, breast, and liver, which often spread to the brain. These cases demand breakthrough solutions to cross the blood-brain barrier (BBB) for targeted therapy. Our mission now encompasses both primary brain tumors and metastatic brain cancers, with a focus on cancers at high risk for brain metastasis
Cancer Type and Brain Metastasis Risk
| Cancer Type | Estimated % of New cases | Brain Metastasis Risk | % Contribution to Brain Metastasis |
|---|---|---|---|
| Breast | 12-15% | 5-20% | 0.6-3.0% |
| Lung | 13-14% | Up to 40% | 2.6-5.6% |
| NSCLC | 80-85% of Lung Cancer | 10-30% | 2.0-4.2% (subset of Lung) |
| Colorectal | 8-10% | 1-4% | 0.08-0.4% |
| Head, Neck | 3-4% | 1-5% | 0.03-0.2% |
| Liver | 2-3% | Up to 15% | 0.3-0.45% |
| Pancreatic | 2-3% | Up to 30% | 0.6-0.9% |
Targeted Nanoparticle-Driven Drug Delivery
Our Carbon Nanoparticle (CNP) platform uses a “Trojan Horse” strategy to enhance BBB penetration. Designed to release therapeutic agents in response to the acidic tumor environment, this pH-tunable platform delivers drugs directly to brain tumors and metastatic lesions. By focusing on high-risk brain cancers, we aim to advance treatment options and improve patient outcomes in complex oncology cases.
Focusing on High-Risk Lung Cancer and Brain Metastasis
Lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC), is a primary focus due to its prevalence and brain metastasis risk (10-30%). Using our CNP technology, we target NSCLC and other high-risk cancers, providing new hope for patients affected by brain metastases
SiNON’s CNPs enable targeted delivery to brain tumors and CNS conditions with advantages in specificity and controlled release. The table below highlights key differences between CNPs, Lipid Nanoparticles (LNPs), and Adeno-Associated Viruses (AAVs), showcasing the unique capabilities of CNPs in delivering therapeutic agents effectively across the blood-brain barrier (BBB)
| Feature | SiNON CNPs | Lipid Nanopartides(LNPs) | Adeno-Associated Viruses(AAVs) |
|---|---|---|---|
| BBB Penetration | Effective access to brain tumors and CNS conditions without mediators | Limited; often requires targeting agents or modifications | Poor; typically requires invasive delivery methods |
| Payload Versatility | Encapsulates small molecules and biologics | Primarily suited for nucleic acids like mRNA | Primarily suited for genetic material(e.g., DNA, RNA) |
| Immunogenicity | Low; minimized immune response for systemic use | Generally low; mild immune response possible with repeated doses | High; significant immune response at therapeutic doses |
| Sustained release | Allows controlled, prolonged release | Typically provides burst or short-term release | No sustained release; requires repeated adminstration |
By leveraging our CNP platform, we offer solutions for drug delivery to brain tumors and metastatic cancers with higher efficacy, better targeting, and lower immunogenicity than existing technologies
We address the challenges of primary brain cancers like glioblastoma and secondary metastases from high-risk cancers. Through advanced, non-invasive therapies that cross the blood-brain barrier, we strive to transform outcomes for complex neurological conditions, opening new pathways for effective treatment in critical areas.
IV Delivery
Non-Toxic
Non-Invasive
Water-Soluble
Self-Fluorescent
Platform(up to 500kDa)
Increase Bio-availability
Slow and Sustained Release